InterVenn Biosciences Joins the WIN and FNIH Biomarker Consortiums to Introduce a Glycoproteomic Option for Liquid Biopsies

SAN FRANCISCO--(BUSINESS WIRE)--InterVenn® Biosciences, a clinical technology company leveraging glycoproteomics to transform the future of healthcare, today announced that it has joined the Worldwide Innovative Network (WIN) Consortium and the Foundation for the National Institutes of Health’s Biomarker Consortium. InterVenn’s innovation in glycoproteomic-based liquid biopsies and translational research provides novel...

Click to view original post